OPKO Health, Inc.
$1.22
▲
0.88%
2026-04-21 08:39:01
www.opko.com
NMS: OPK
Explore OPKO Health, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$926.06 M
Current Price
$1.22
52W High / Low
$1.6 / $1.09
Stock P/E
—
Book Value
$1.67
Dividend Yield
—
ROCE
-12.27%
ROE
-17.14%
Face Value
—
EPS
$-0.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,275
Beta
1.49
Debt / Equity
31.29
Current Ratio
3.97
Quick Ratio
3.52
Forward P/E
-3.52
Price / Sales
1.47
Enterprise Value
$912.89 M
EV / EBITDA
-7.17
EV / Revenue
1.5
Rating
None
Target Price
$3.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NeoGenomics, Inc. | $8.23 | — | $1.06 B | — | -6.93% | -12.43% | $13.74 / $4.72 | $6.49 |
| 2. | RadNet, Inc. | $57.85 | — | $4.48 B | — | 2.63% | 1.37% | $85.84 / $46.76 | $14.08 |
| 3. | ENDRA Life Sciences Inc. | $6.01 | — | $7.46 M | — | -281.17% | -2.92% | $11.96 / $2.9 | $0.22 |
| 4. | Labcorp Holdings Inc. | $271.17 | 25.93 | $22.36 B | 1.07% | 9.74% | 10.51% | $293.72 / $209.38 | $104.86 |
| 5. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 6. | XWELL, Inc. | $1.2 | — | $9.7 M | — | -75.03% | -275.96% | $2.2 / $0.26 | $-1.1 |
| 7. | iSpecimen Inc. | $0.13 | — | $4.05 M | — | -355.55% | -3.28% | $3.18 / $0.1 | $0.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 148.45 M | 151.67 M | 156.81 M | 149.95 M | 183.64 M | — |
| Operating Profit | -38.32 M | -53.52 M | -59.98 M | -67.17 M | -33.14 M | — |
| Net Profit | -31.26 M | 21.63 M | -148.44 M | -67.61 M | 14.03 M | — |
| EPS in Rs | -0.04 | 0.03 | -0.2 | -0.09 | 0.02 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 606.88 M | 713.14 M | 863.5 M | 1 B |
| Operating Profit | -218.99 M | -273.56 M | -158.06 M | -246.12 M |
| Net Profit | -225.68 M | -53.22 M | -188.86 M | -328.4 M |
| EPS in Rs | -0.3 | -0.07 | -0.25 | -0.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.93 B | 2.2 B | 2.01 B | 2.17 B |
| Total Liabilities | 663.99 M | 834.76 M | 622.48 M | 605.61 M |
| Equity | 1.27 B | 1.37 B | 1.39 B | 1.56 B |
| Current Assets | 581.88 M | 662.09 M | 309.48 M | 394.52 M |
| Current Liabilities | 146.68 M | 193.1 M | 200.05 M | 213.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -178.54 M | -183.49 M | -28.2 M | -95.19 M |
| Investing CF | 230.3 M | 352.21 M | -18.2 M | 91.04 M |
| Financing CF | -118.06 M | 184.17 M | -11.3 M | 22.97 M |
| Free CF | -190.82 M | -208.5 M | -44.47 M | -119.77 M |
| Capex | -12.28 M | -25.01 M | -16.27 M | -24.58 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -17.41% | -14.01% | — | — |
| Earnings Growth % | 71.82% | 42.49% | — | — |
| Profit Margin % | -7.46% | -21.87% | -32.7% | — |
| Operating Margin % | -38.36% | -18.3% | -24.51% | — |
| Gross Margin % | 30.64% | 36.84% | 28.7% | — |
| EBITDA Margin % | 18.97% | -7.59% | -26.97% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.